No oral tirzepatide tablet has been tested in humans in any published study
Dev Dyn (2001) 221(1):8191
Growth in select inpatient procedures: Despite the ongoing shift to outpatient care, select inpatient procedures can expect robust growth over the next decade, including aortic valve replacement (111%), left atrial appendage closure (80%), implantable loop recorder (72%), endovascular procedures (57%), and transplants (37%)
It represents the next generation of weight loss medications because it activates both GLP-1 and GIP receptors, a dual mechanism that clinical trials showed produces even greater weight loss than semaglutide alone
The most common side effects are usually related to your stomach and gut, such as feeling sick (nausea), vomiting, diarrhoea, or constipation